Clinical Trials

72 enrolled

Phase 3 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04971226 2026-03-10

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

406 enrolled 18 charts 1 FDA

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04877522 2026-03-06

Asciminib Roll-over Study

Phase 4 Recruiting

347 enrolled

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07454850 2026-03-06

A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait

Not yet recruiting

400 enrolled

125 enrolled 18 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT02730299 2026-02-25

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Phase 3 Completed

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Phase 1/2 Recruiting

12 enrolled

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05456191 2026-02-06

ASC4START

Phase 3 Active not recruiting

568 enrolled

Leukemia, Myeloproliferative Disorders, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05362773 2026-01-13

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

130 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

NCT06163430 2026-01-12

CARDINAL

Phase 1/2 Recruiting

180 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05304377 2026-01-09

CML

200 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT03874858 2026-01-06

DANTE

124 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04360005 2025-12-05

Managed Access Programs for ABL001, Asciminib

Available

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03578367 2025-11-10

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

104 enrolled 11 charts

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04260022 2025-11-05

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

242 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Phase 1 Terminated

84 enrolled

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT07188428 2025-09-23

Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment

2,298 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06514534 2025-09-22

ASC4TARGET

Phase 2 Recruiting

20 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04925479 2025-09-17

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Phase 1/2 Recruiting

44 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06986772 2025-09-04

TGRX-678 Pharmacokinetic Mass Balance

Phase 1 Completed

6 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 1 FDA

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07150793 2025-09-02

A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan

754 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07145411 2025-08-28

HOPE

Recruiting

10 enrolled

Anemia, Aplastic, Anemia, Sickle Cell, Lymphoma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06787144 2025-07-01

CML

21 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Phase 1 Completed

38 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT06423911 2025-06-03

POLARIS-2

Phase 3 Recruiting

285 enrolled

Phase 1 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT04013685 2025-05-02

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

255 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04795427 2025-04-18

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

84 enrolled

233 enrolled 10 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03106779 2025-04-08

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Phase 3 Completed

Phase 2 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04233346 2025-04-04

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

93 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05282108 2025-03-26

CARCML

Recruiting

240 enrolled

Leukemia, Neoplasms, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

144 enrolled

Phase 1 Active not recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05434312 2025-02-24

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

90 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06088888 2025-02-21

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

90 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06453902 2025-02-21

TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

Phase 2 Recruiting

40 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase

NCT06692803 2024-11-18

ABL-2022-03

2,043 enrolled

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05260203 2024-11-06

MargheRITA

Phase NA Completed

124 enrolled

Treatment Adherence and Compliance, Amyloidosis, Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Multiple Myeloma, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Neoplasms, Plasma Cell

NCT06672263 2024-11-04

A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia

Phase 1 Not yet recruiting

120 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03459534 2024-10-28

A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs

Phase 3 Recruiting

173 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00285259 2024-10-21

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

112 enrolled

Communicable Diseases, Cytomegalovirus Infections, Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Viremia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00042003 2024-08-02

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

40 enrolled

Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00522990 2024-08-02

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Phase 1/2 Terminated

48 enrolled

Phase 1/2 Active not recruiting

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02629692 2024-07-31

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

122 enrolled

Phase 1 Not yet recruiting

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT06530810 2024-07-31

Study of HS-10382 Combination in Patients With Chronic Myeloid Leukemia (CML)

100 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

NCT00346632 2024-05-17

An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia

Phase 1 Terminated

37 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02501330 2024-04-30

BLF

702 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02455024 2024-04-04

OMNI

Terminated

3 enrolled

Blast Crisis, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02081378 2024-03-18

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Phase 1 Completed

326 enrolled 1 FDA